Trials / Terminated
TerminatedNCT00368186
Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants.
An Open, Multicenter Clinical Trial to Investigate the Immunogenicity and Safety of the Pneumococcal 7-Valent Conjugate Vaccine (PREVENAR) in Sickle Cell Disease Infants.
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 51 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 57 Days – 112 Days
- Healthy volunteers
- Not accepted
Summary
The primary objectives of this study were to assess the immunogenicity and the tolerance of the heptavalent pneumococcal conjugate vaccine (Prevenar) in young infants (2 months of age) with sickle cell disease when administred at 2,3, and 4 months of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Pneumo 23 |
Timeline
- Start date
- 2001-05-01
- Completion
- 2002-11-01
- First posted
- 2006-08-24
- Last updated
- 2006-08-24
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00368186. Inclusion in this directory is not an endorsement.